

# Test Bulletin



Dear Healthcare Provider,

The information contained here may be very important to your practice. Please take a moment to review this document.

## **Deamidated Gliadin, Tissue Transglutaminase**

**November 2, 2022**

Effective November 2, 2022, Alverno Laboratories will be performing deamidated gliadin and tissue transglutaminase via a new chemiluminescent methodology. The reference cutoff for negative results will remain the same at <20 Units. However, quantitative results from the new methodology should not be used interchangeably with different manufacturers' assay methods.

## **Preventing Harm Test Code – Use According to Regulations – See Disclaimer in Description**

**November 2022**

As the clinician with a direct patient relationship, you are responsible for determining the appropriate release of information in accordance with applicable law. Alverno is not responsible for determining whether a lab result must not be released to a patient through the patient portal. If you determine, in your professional judgment, that a result must be temporarily withheld from a patient, you must document this decision appropriately in your patient chart and select the code PRHAR as an orderable test. By selecting the code, you have determined that an Information Blocking exception applies to suppress the release of the patient's results in Alverno's patient portal, in accordance with your organization's Information Blocking policies and procedures.

Seek legal counsel if you are not familiar with your obligations with respect to HIPAA and the Information Blocking Rules. Alverno will not be held liable for following your instructions to release or withhold test results.

If you choose to withhold a test result, all results in that order will be withheld by Alverno due to technical infeasibility. Results will be held for 5 days to allow you time to contact the patient first. If the patient contacts Alverno for results on this order within the 5-day time frame, the patient will be directed to contact your office for results.

## **Client Community Users Update**

**January 1, 2023**

For our clients using the electronic system on our website for adding additional tests to a current order, please note that effective January 1, 2023, the Internet Explorer (IE) browser will no longer be supported. This means for any users currently submitting add-ons from the IE web browser, the request will not be received by Alverno and therefore testing will not be performed. Prior to the effective date, please upgrade to a supported browser such as Google Chrome or Microsoft Edge to submit your add-on testing electronically. If you have any questions, please contact our Client Services team at 800-937-5521.